AEZS.TO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 22:57):

Stats
Šios dienos apimtis	845.00
Vidutinė apimtis	559.00
Rinkos kapitalizacija	13.95M
EPS	$0 ( 2024-05-06 )
Last Dividend	$0.0825 ( 1999-08-11 )
Next Dividend	$0 ( N/A )
P/E	-0.620
ATR14	$0 (0.00%)

AETERNA ZENTARIS INC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
HZM.TO	0.971
IGM.TO	0.958
BRE.TO	0.958
SOLG.TO	0.957
D-UN.TO	0.956
SGR-UN.TO	0.956
CVD.TO	0.954
AP-UN.TO	0.95
TRZ.TO	0.949
MPCT-UN.TO	0.949

10 Labiausiai neigiamai susiję koreliacijos
QBTL.TO	-0.93
SBB.TO	-0.919
SNC.TO	-0.915
IAF-PI.TO	-0.915
SFC.TO	-0.902
E.TO	-0.895
PEY.TO	-0.894
RQK.TO	-0.889
U-UN.TO	-0.878
VLE.TO	-0.865

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AETERNA ZENTARIS INC Finansinės ataskaitos

Annual	2023
Pajamos:	$4.50M
Bruto pelnas:	$4.28M (95.06 %)
EPS:	$-3.41

FY	2023
Pajamos:	$4.50M
Bruto pelnas:	$4.28M (95.06 %)
EPS:	$-3.41

FY	2022
Pajamos:	$5.64M
Bruto pelnas:	$5.48M (97.22 %)
EPS:	$-6.22

FY	2021
Pajamos:	$5.26M
Bruto pelnas:	$5.17M (98.29 %)
EPS:	$-1.820

Financial Reports:

No articles found.

AETERNA ZENTARIS INC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

AETERNA ZENTARIS INC Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0825	1999-08-11
Last Dividend	$0.0825	1999-08-11
Next Dividend	$0	N/A
Payout Date	2007-01-02
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0825	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-07)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
1999	$0	0.00%
2000	$0	0.00%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for TSX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
VEF.TO	Dividend Junior	2023-09-18	Quarterly	13	1.44%
MUMC.TO	Dividend Junior	2023-06-29	Semi-Annually	8	0.44%
DIV.TO	Dividend King	2023-09-14	Monthly	11	4.80%
ZBAL.TO	Dividend Junior	2023-06-28	Quarterly	6	1.30%
SES.TO	Dividend King	2023-09-28	Quarterly	12	1.90%
HDIV.TO	Dividend Knight	2023-08-30	Monthly	4	3.89%
BMO-PF.TO	Dividend King	2023-07-27	Quarterly	6	3.03%
WTE.TO	Dividend King	2023-06-29	Quarterly	22	4.23%
PAAS.TO	Dividend Knight	2023-08-18	Quarterly	17	1.02%
EMA.TO	Dividend Knight	2023-07-31	Quarterly	30	2.84%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-3.70	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.450	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.636	1.500	-8.18	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	8.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.57	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	7.49	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00754	-1.500	9.87	-10.00	[0 - 0.6]
interestCoverageTTM	-375.17	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-3.52	2.00	-1.175	-2.35	[0 - 30]
freeCashFlowPerShareTTM	-3.53	2.00	-1.764	-3.53	[0 - 20]
debtEquityRatioTTM	0.0153	-1.500	9.94	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.951	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-4.00	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-61.35	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.122	0.800	-2.52	-2.02	[0.5 - 2]
Total Score				-1.290

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.28	1.000	-0.332	0	[1 - 100]
returnOnEquityTTM	-0.636	2.50	-5.26	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-3.53	2.00	-1.176	-3.53	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.52	2.00	-1.175	-2.35	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.723	1.500	1.849	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.81	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.23

AETERNA ZENTARIS INC

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.